Ojas Mehta, DO
Nephrology · Monroe, NJNPI 1255504031
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 49.0% of the total. Reporting peaked in 2021 at $4,911 and has fallen 85.6% since, to $707 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $44.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$5K
- Fresenius USA Marketing, Inc.$1K
- AstraZeneca$445
- Vifor Pharma, Inc.$414
- Takeda Pharmaceuticals U.S.A., Inc.$327
- Amgen$315
- plus $2K from 26 others
Across 10 payments — averaging $1790.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aurinia Pharma U.S., Inc.$18K
What the payments were for
- Consulting fees$5,77858%
- Speaking & faculty fees$4755%
- Food & beverage$3,65237%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $4,862 |
| Fresenius USA Marketing, Inc. | 14 | $1,259 |
| AstraZeneca(2 entities) | 32 | $445 |
| Vifor Pharma, Inc. | 16 | $414 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $327 |
| Amgen(2 entities) | 22 | $315 |
| Johnson & Johnson | 2 | $256 |
| Baxter Healthcare | 3 | $219 |
| Bayer | 13 | $214 |
| Daiichi Sankyo Inc. | 12 | $170 |
| GSK | 11 | $158 |
| Boehringer Ingelheim | 8 | $136 |
| Aurinia Pharma U.S., Inc. | 10 | $130 |
| Travere Therapeutics, Inc. | 9 | $126 |
| Mozarc Medical US LLC | 1 | $108 |
| Calliditas Therapeutics US Inc. | 6 | $94 |
| Ardelyx, Inc. | 5 | $84 |
| Ultragenyx Pharmaceutical Inc. | 6 | $78 |
| OPKO Pharmaceuticals, LLC | 6 | $76 |
| Mallinckrodt Hospital Products Inc. | 5 | $76 |
| Akebia Therapeutics Inc | 4 | $66 |
| Mallinckrodt Enterprises LLC | 4 | $58 |
| Shire North American Group Inc | 4 | $49 |
| Novartis | 2 | $43 |
| Renalytix AI, Inc. | 2 | $33 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| Vantive US Healthcare LLC | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Covidien LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,927 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 27 | $60,859 |
| KerendiaFinerenone | 50 | $28,362 |
| FarxigaDapagliflozin Propanediol | 17 | $27,862 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $21,541 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 51 | $15,491 |
| Midodrine Hcl | 27 | $2,876 |
| Sevelamer Carbonate | 19 | $2,637 |
| Amlodipine Besylate | 258 | $2,442 |
| Allopurinol | 56 | $2,342 |
| Valsartan | 70 | $2,113 |
| Torsemide | 83 | $1,598 |
| Indapamide | 83 | $1,561 |
| Atorvastatin Calcium | 97 | $1,529 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 39 | $1,447 |
| Losartan Potassium | 103 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $445 | $49,40330 claims |
| BayerKerendia | $214 | $28,36250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Monroe
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
- Joseph AlbaneseBrick$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.